WARRINGTON, Pa., Sept. 6, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the full publication of previously described results of a lung deposition study condu

SAN FRANCISCO, Sept. 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) announced the pricing on September 5, 2019 of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Se

WALTHAM, Mass., Sept. 6, 2019 /PRNewswire/ -- 42 North Dental, a leading Dental Support Organization in New England, has added All Dental Center in Westborough and Watertown and Fresh Pond Dental in Cambridge to their portfolio of supported dental practices. The practi

SCHAFFHAUSEN, Switzerland, Sept. 6, 2019 /PRNewswire/ -- Occlutech AG announced today that its atrial flow regulator, the Occlutech AFR device, has obtained CE mark approval clearing it for sales on the European CE regulated market. Occlutech AFR is a next generation intra-atrial shunt device, intended to treat heart failure symptoms by decompressing abnormal intra-atria

PALO ALTO, Calif., Sept. 6, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will participate in the Morgan Stanley Global Healthcare Conference in New York, NY on

LOS ANGELES, Sept. 6, 2019 /PRNewswire/ --WHO:        Stars of the Netflix series

WASHINGTON, Sept. 6, 2019 /PRNewswire/ -- In a matter of days, every health center in America stands to lose more than 70% of their federal grant funding without Congress extending the funding by September 30. Community Health Centers provide care to 29 million people across the country according to the National Association of Community Health Centers (NAC

KRAKOW, Poland, Sept. 6, 2019 /PRNewswire/ -- Selvita (WSE: SLV) today announced that the first patient enrolled in the Phase 1b study of company's selective CDK8 inhibitor, SEL120, has received the first dose. SEL120 is being initially investigated in the treatment of patients with acute myeloid leukemi

GENEVA, Sept. 6, 2019 /PRNewswire/ -- Cleft lip and palate (clefts) are the most common birth difference of the face and mouth. Clefts happen when certain body parts and structures do not fuse together during fetal development and impact the development of the mouth, gums, and palate. Even after having cleft surgery, children can

TOKYO, OSAKA, Japan, LONDON, and BASEL, Switzerland, Sept. 5, 2019 /PRNewswire/ -- Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading Japanese pharmaceutical company, and Roivant Sciences Ltd., a technology-enabled healthcare company, today announced that